On July 23, 2026, medical staff at the Melathro Agoniston EOKA facility in Cyprus administered the first dose of the monoclonal antibody donanemab to a 72-year-old patient. This event marks the first time this pioneering treatment for early-stage Alzheimer’s disease has been provided in the country.

The patient, who began exhibiting symptoms of memory and behavioral changes approximately one year ago, underwent extensive clinical evaluations before being cleared for the therapy. According to Professor of Neurology Giorgos Kaponidis, the scientific and medical director at the facility, the patient met strict medical criteria necessary to receive the drug, which is sold under the brand name Kisunla. The medication works by targeting beta-amyloid plaques in the brain to slow the progression of the disease.

The treatment has been authorized for use within the European Union since September 2025. By implementing this protocol, local medical specialists aim to provide a new therapeutic avenue for early-stage patients, potentially improving outcomes for those identified during the initial phases of the disease.